Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:52:22.003Z.
Calculation as of: 2026-10-06T18:52:22.003Z.
Quote observation: 2026-10-06T18:50:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b626f321e8bf7fc1aa576344fb562ad2ba7a1b85fa36d8388ebfe6a76482c652
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2024-09-30.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
PS RATIO AVG TTM
N/A
PS RATIO AVG 3Y
N/A
PS RATIO AVG 5Y
N/A
PS RATIO AVG 10Y
N/A
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$30263.00
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$70876.00
PS Ratio
1.79
TTM Avg
236.43
3Y Avg
15964481498759.19
5Y Avg
12825398057992.62
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NewGenIvf Group Limited (NIVF) | $5989.00 | N/A | N/A | N/A | N/A |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $30263.00 | N/A | N/A | N/A | N/A |
| Zhongchao Inc. (ZCMD)vs › | $31083.00 | N/A | N/A | N/A | N/A |
| Akanda Corp. (AKAN)vs › | $61819.00 | N/A | N/A | N/A | N/A |
| PRF Technologies Ltd. (PRFX)vs › | $70876.00 | 1.79 | 236.43 | 15964481498759.19 | 12825398057992.62 |
| Psyence Biomedical Ltd. (PBM)vs › | $96215.00 | N/A | N/A | N/A | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $109777.00 | N/A | N/A | N/A | N/A |
| SciSparc Ltd. (SPRC)vs › | $242924.00 | N/A | N/A | N/A | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $357350.00 | N/A | N/A | N/A | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | N/A | N/A | N/A | N/A |
Half-year reporter: no trailing two-half-year basis, because the newest reported periods are not each a half-year of 150 to 215 days.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2024-09-30 | 7029.85 |
| 2024-09-27 | 6460.42 |
| 2024-09-26 | 6595.01 |
| 2024-09-25 | 6895.26 |
| 2024-09-24 | 6025.58 |
| 2024-09-23 | 6243.00 |
| 2024-09-20 | 6698.55 |
| 2024-09-19 | 6532.89 |
| 2024-09-18 | 7071.26 |
| 2024-09-17 | 6936.67 |
| 2024-09-16 | 7216.21 |
| 2024-09-13 | 7236.91 |
| 2024-09-12 | 7247.27 |
| 2024-09-11 | 7247.27 |
| 2024-09-10 | 6988.44 |
| 2024-09-09 | 7247.27 |
| 2024-09-06 | 7050.56 |
| 2024-09-05 | 7299.03 |
| 2024-09-04 | 7661.40 |
| 2024-09-03 | 8655.31 |
| 2024-08-30 | 8903.79 |
| 2024-08-29 | 9110.85 |
| 2024-08-28 | 9359.33 |
| 2024-08-27 | 9835.58 |
| 2024-08-26 | 10011.58 |
| 2024-08-23 | 11740.57 |
| 2024-08-22 | 9628.51 |
| 2024-08-21 | 8852.02 |
| 2024-08-20 | 8603.54 |
